| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
110.03(B) |
| Last
Volume: |
750,617 |
Avg
Vol: |
759,306 |
| 52
Week Range: |
$692.45 - $1071.19 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
192,108 |
255,165 |
311,759 |
469,743 |
| Total Sell Value |
$188,697,290 |
$247,812,013 |
$294,950,701 |
$405,465,351 |
| Total People Sold |
7 |
14 |
16 |
18 |
| Total Sell Transactions |
18 |
43 |
67 |
128 |
| End Date |
2024-03-31 |
2023-12-29 |
2023-06-30 |
2022-06-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Landry Robert E |
SVP Finance & CFO |
• – – |
2018-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
17,348 |
|
- |
|
| Mccourt Marion |
SVP Commercial |
• – – |
2018-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
12,500 |
|
- |
|
| Yancopoulos George |
President and CSO |
• • – |
2018-11-16 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,176 |
483,601 |
|
- |
|
| Vagelos P Roy |
Chairman of the Board |
• • – |
2018-11-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
16,161 |
314,877 |
|
- |
|
| Vagelos P Roy |
Chairman of the Board |
• • – |
2018-11-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
19,202 |
331,038 |
|
- |
|
| Vagelos P Roy |
Chairman of the Board |
• • – |
2018-11-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
37,209 |
350,240 |
|
- |
|
| Yancopoulos George |
President and CSO |
• • – |
2018-11-01 |
4 |
GD |
$0.00 |
$0 |
I/I |
24,643 |
0 |
|
- |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2018-10-25 |
4 |
GA |
$0.00 |
$0 |
I/I |
2,950 |
2,950 |
|
- |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2018-10-25 |
4 |
GD |
$0.00 |
$0 |
I/I |
2,950 |
1,397 |
|
- |
|
| Vagelos P Roy |
Chairman of the Board |
• • – |
2018-10-04 |
4 |
GD |
$0.00 |
$0 |
I/I |
521 |
147,413 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2018-09-28 |
4 |
AS |
$410.00 |
$290,690 |
D/D |
(709) |
12,000 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2018-09-28 |
4 |
OE |
$273.67 |
$194,032 |
D/D |
709 |
12,709 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2018-09-27 |
4 |
AS |
$400.00 |
$800,000 |
D/D |
(2,000) |
12,000 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2018-09-27 |
4 |
OE |
$273.67 |
$547,340 |
D/D |
2,000 |
14,000 |
|
- |
|
| Brown Michael S |
Director |
– • – |
2018-09-27 |
4 |
AS |
$390.23 |
$784,524 |
D/D |
(2,000) |
0 |
|
- |
|
| Brown Michael S |
Director |
– • – |
2018-09-27 |
4 |
OE |
$273.67 |
$547,340 |
D/D |
2,000 |
2,000 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2018-09-24 |
4 |
AS |
$387.29 |
$777,290 |
D/D |
(2,000) |
12,000 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2018-09-24 |
4 |
OE |
$273.67 |
$547,340 |
D/D |
2,000 |
13,000 |
|
- |
|
| Landry Robert E |
SVP Finance & CFO |
• – – |
2018-09-10 |
4 |
D |
$395.29 |
$889,798 |
D/D |
(2,251) |
4,848 |
|
- |
|
| Sanofi-Aventis |
|
• • • |
2018-09-06 |
4 |
S |
$406.68 |
$42,519,249 |
I/I |
(104,552) |
23,654,384 |
|
- |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2018-08-30 |
4 |
GA |
$0.00 |
$0 |
I/I |
50 |
4,347 |
|
- |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2018-08-30 |
4 |
GD |
$0.00 |
$0 |
D/D |
50 |
1,421 |
|
- |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2018-08-30 |
4 |
OE |
$21.25 |
$1,063 |
D/D |
50 |
200 |
|
- |
|
| Vagelos P Roy |
Chairman of the Board |
• • – |
2018-08-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
12,500 |
387,449 |
|
- |
|
| Yancopoulos George |
President and CSO |
• • – |
2018-08-22 |
4 |
GD |
$0.00 |
$0 |
I/I |
3,211 |
484,777 |
|
- |
|
1367 Records found
|
|
Page 38 of 55 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.17 (0.02%) 
